Retrospective analysis of the consequences of acid suppressive therapy on ketoconazole efficacy in advanced castration-resistant prostate cancer

Annals of Pharmacotherapy

Volumn 44, Issue 10, 2010, Pages 1538-1544

  Keisner, Sidney V ^a,b   Shah, Sachin R ^a,b   Jean, Gary W ^a,b   Ussery, Sarah M Gressett ^b   Dowell, Jonathan E ^c,d  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^c Veterans Affairs North Texas Health Care System   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Drug interactions; Ketoconazole; Prostate neoplasms; Proton pump inhibitors

Indexed keywords

ANTIANDROGEN; KETOCONAZOLE; OMEPRAZOLE; PROSTATE SPECIFIC ANTIGEN; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ANTIANDROGEN THERAPY; ARTICLE; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CLINICAL EVALUATION; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RETROSPECTIVE STUDY; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; DISEASE-FREE SURVIVAL; DRUG INTERACTIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; GASTROINTESTINAL DISEASES; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77957674315     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P225     Document Type: Article

References (21)

1. Statistics for 2010. American Cancer Society. www.cancer.org (accessed 2010 Jul 4).
2. The NCCN Clinical Practice Guidelines in oncology prostate cancer (version 1.2010). www.nccn.org/professionals/physician-gls/PDF/prostate.pdf (accessed 2010 Mar 18).
3. Pont A, Williams PL, Azhar S, et al. Ketoconazole blocks testosterone synthesis. Arch Intern Med 1982;142:2137-40.
4. Reid AH, Attard G, Barrie E, de Bono JS. CYP17 as a hormonal strategy for prostate cancer. Nat Clin Pract Urol 2008;5:610-20.
5. Ketoconazole. In: DRUGDEX system. Greenwood Village, CO: Thomson Healthcare. Updated periodically (accessed 2010 Mar 4).
6. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004;22:1025-33.
7. Small EJ, Baron A, Bok R. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer 1997;80:1755-9.
8. Small EJ, Baron AD, Fippin L, Apodaca D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 1997;157:1204-7.
9. Lelawongs P, Barone JA, Colaizzi JL, et al. Effect of food and gastric acidity on absorption of orally administered ketoconazole. Clin Pharm 1988;7:228-35.
10. Chin TW, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob Agents Chemother 1995;39:1671-5.
11. Piscitelli SC, Goss TF, Wilton JH, D'Andrea DT, Goldstein H, Schentag JJ. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother 1991;35:1765-71.
12. IMS study finds decline in prescription drug market growth. Drug Store News. Findarticles.com (accessed 2009 Aug 25).
13. Nakabayashi M, Xie W, Regan MM, Jackman DM, Kantoff PW, Oh WK. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. Cancer 2006;107:975-81.
14. Wilkinson S, Chodak G. An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer. Eur Urol 2004;45:581-4.
15. Ngo LS, Yeo A, Wong AS, Tay MH. Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and the Cancer Institute, Singapore. Ann Acad Med Singapore 2007;36:811-4.
16. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
17. Howden CW, Forrest JA, Reid JL. Effects of single and repeated doses of omeprazole on gastric acid and pepsin secretion in man. Gut 1984;25:707-10.
18. Lind T, Cederberg C, Ekenved G, Hagland U, Olbe L. Effect of omeprazole - a gastric proton pump inhibitor - on pentagastrin stimulated acid secretion in man. Gut 1983;24:270-6.
19. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-7.
20. Talebi TN, Manoharan M, Soloway MS, Singal R. Efficacy of high-dose ketoconazole in castration-resistant, metastatic prostate cancer patients previously treated with docetaxel chemotherapy: single institution retrospective review (abstract 163). J Clin Oncol 2010;28(suppl): e15151.
21. Galsky MD, Simon K, Sonpavde G, et al. Ketoconazole retains activity in patients with docetaxel refractory prostate cancer. 2009;20:965-6.